REG - 3i Group PLC - Director/PDMR Shareholding

3iAnnouncement

03/06/2020 13:35

RNS Number : 8488O
  
3i Group PLC
  
03 June 2020
  
 

Market Abuse Regulation
 
MAR Article 19
 
On 2 June 2020, 3i Group plc (the "Company") was notified of the following.  
 
On 1 June 2020 share awards under the 3i Group Deferred Bonus Plan (the "Plan") held by Simon Borrows, a Director and person discharging managerial responsibilities ("PDMR") vested.  On that date 170,718 ordinary shares of 73 19/22p each (ISIN: GB00B1YW4409) in the Company ("Shares") ceased to be subject to restrictions under the Plan.
 
On 1 June 2020 share awards under the Plan held by the PDMRs named in the table below vested.  On that date the Shares shown in the column headed "Shares acquired" ceased to be subject to restrictions under the Plan.  The Shares shown in the column headed "Shares sold" were sold on 1 June 2020 at a price of 835.52p per share.
 



PDMR


Shares acquired


Shares sold




K J Dunn


61,010


28,745




P J White


314,471


314,471




J S Wilson


74,801


35,240




 


 


 




On 1 June 2020 cash settled awards vesting under the Plan (under which a bonus is paid by reference to a number of notional Shares) held by the PDMRs named in the table below became payable.  On that date a bonus became payable in respect of a number of notional Shares shown in the column headed "Notional Shares vesting" based on a value equivalent to 827.6p per share.
 




PDMR


Notional Shares vesting


 




R Collins


6,905


 




P De Jong


18,440


 




P Wirtz


21,837


 



 
On 1 June 2020 Kevin Dunn, a PDMR, acquired for nil cost 19,470 Shares on the release of a share award under the 3i Group Discretionary Share Plan and sold these Shares on the same date at a price of 835.52p per share.
 
The place of these transactions was the London Stock Exchange.
 
Ends 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHUPUBPQUPUGPW